Mass spectrometric characterization of amyloid-β species in the 7PA2 cell model of Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 33, Issue 1, 2013, Pages 85-93

  Portelius, Erik ^a   Olsson, Maria ^a   Brinkmalm, Gunnar ^a   Rüetschi, Ulla ^a   Mattsson, Niklas ^a   Andreasson, Ulf ^a   Gobom, Johan ^a   Brinkmalm, Ann ^a   Hölttä, Mikko ^a   Blennow, Kaj ^a   Zetterberg, Henrik ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; amyloid ; biomarkers; dimers; mass spectrometry; oligomers

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[5-40]; MONOMER; OLIGOMER; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IMMUNOREACTIVITY; MASS SPECTROMETRY; MOLECULAR WEIGHT; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN STRUCTURE; WESTERN BLOTTING;

EID: 84872466519     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-120994     Document Type: Article

References (25)

1. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol 30, 572-580.
2. DeKosky ST, Scheff SW, Styren SD (1996) Structural correlates of cognition in dementia: Quantification and assessment of synapse change. Neurodegeneration 5, 417-421. (Pubitemid 27077903)
3. Coleman PD, Yao PJ (2003) Synaptic slaughter in Alzheimer's disease. Neurobiol Aging 24, 1023-1027. (Pubitemid 37487880)
4. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403. (Pubitemid 44108123)
5. Walsh DM, Selkoe DJ (2007) A oligomers - a decade of discovery. J Neurochem 101, 1172-1184.
6. Holtzman DM, Morris JC, Goate AM (2011) Alzheimer's disease: The challenge of the second century. Sci Transl Med 3, 77sr71.
7. Koffie RM, Hyman BT, Spires-Jones TL (2011) Alzheimer's disease: Synapses gone cold. Mol Neurodegener 6, 63.
8. Andreasson U, Portelius E, Andersson ME, Blennow K, Zetterberg H (2007) Aspects of -amyloid as a biomarker for Alzheimer's disease. Biomarkers Med 1, 59-78.
9. Vassar R, Kovacs DM, Yan R, Wong PC (2009) The -secretase enzyme BACE in health and Alzheimer's disease: Regulation, cell biology, function, and therapeutic potential. J Neurosci 29, 12787-12794.
10. Selkoe DJ, Wolfe MS (2007) Presenilin: Running with scissors in the membrane. Cell 131, 215-221. (Pubitemid 47576152)
11. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539. (Pubitemid 34288854)
12. Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ (2000) The oligomerization of amyloid-protein begins intracellularly in cells derived from human brain. Biochemistry 39, 10831-10839.
13. Mattsson N, Rajendran L, Zetterberg H, Gustavsson M, Andreasson U, Olsson M, Brinkmalm G, Lundkvist J, Jacobson LH, Perrot L, Neumann U, Borghys H, Mercken M, Dhuyvetter D, Jeppsson F, Blennow K, Portelius E (2012) BACE1 inhibition induces a specific cerebrospinal fluid -amyloid pattern that identifies drug effects in the central nervous system. PLoS One 7, e31084.
14. Podlisny MB, Ostaszewski BL, Squazzo SL, Koo EH, Rydell RE, Teplow DB, Selkoe DJ (1995) Aggregation of secreted amyloid -protein into sodium dodecyl sulfatestable oligomers in cell culture. J Biol Chem 270, 9564-9570.
15. Walsh DM, Townsend M, Podlisny MB, Shankar GM, Fadeeva JV, El Agnaf O, Hartley DM, Selkoe DJ (2005) Certain inhibitors of synthetic amyloid -peptide (A-) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J Neurosci 25, 2455-2462.
16. Klyubin I,Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang L, Anwyl R, Selkoe DJ, Rowan MJ (2005) Amyloid protein immunotherapy neutralizes A oligomers that disrupt synaptic plasticity in vivo. Nat Med 11, 556-561. (Pubitemid 40685979)
17. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH (2005) Natural oligomers of the amyloid- protein specifically disrupt cognitive function. Nat Neurosci 8, 79-84. (Pubitemid 41236735)
18. Portelius E, Brinkmalm G, Tran AJ, Zetterberg H, Westman-Brinkmalm A, Blennow K (2009) Identification of novel APP/A isoforms in human cerebrospinal fluid. Neurodegener Dis 6, 87-94.
19. BrinkmalmG, Portelius E, O? hrfelt A,Mattsson N, Persson R, Gustavsson MK, Vite CH, Gobom J, M°ansson J-E, Nilsson J, Halim A, Larson G, R?uetschi U, Zetterberg H, Blennow K, Brinkmalm A (2012) An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid and amyloid precursor protein in human and cat cerebrospinal fluid. J Mass Spectrom 47, 591-603.
20. Stachel SJ, Coburn CA, Steele TG, Jones KG, Loutzenhiser EF, Gregro AR, Rajapakse HA, Lai MT, Crouthamel MC, Xu M, Tugusheva K, Lineberger JE, Pietrak BL, Espeseth AS, Shi XP, Chen-Dodson E, Holloway MK, Munshi S, Simon AJ, Kuo L, Vacca JP (2004) Structure-based design of potent and selective cell-permeable inhibitors of human -secretase (BACE-1). J Med Chem 47, 6447-6450. (Pubitemid 39657304)
21. Portelius E, Tran AJ, Andreasson U, Persson R, Brinkmalm G, Zetterberg H, Blennow K,Westman-Brinkmalm A (2007) Characterization of amyloid peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J Proteome Res 6, 4433-4439. (Pubitemid 350158518)
22. Miller DL, Papayannopoulos IA, Styles J, Bobin SA, Lin YY, Biemann K, Iqbal K (1993) Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch Biochem Biophys 301, 41-52. (Pubitemid 23227174)
23. Naslund J, Schierhorn A, Hellman U, Lannfelt L, Roses AD, Tjernberg LO, Silberring J, Gandy SE,Winblad B, Greengard P, et al. (1994) Relative abundance of Alzheimer A amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci U S A 91, 8378-8382. (Pubitemid 24273667)
24. Portelius E, Bogdanovic N, Gustavsson MK, Volkmann I, Brinkmalm G, Zetterberg H, Winblad B, Blennow K (2010) Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathol 120, 185-193.
25. Pike CJ, Overman MJ, Cotman CW (1995) Amino-terminal deletions enhance aggregation of -amyloid peptides in vitro. J Biol Chem 270, 23895-23898.